Pulmonx (NASDAQ:LUNG) CFO Mehul Joshi Sells 7,936 Shares

Key Points

• Pulmonx CFO Mehul Joshi sold 7,936 shares at an average price of $1.60, totaling $12,697.60, reducing his ownership by 3.67% to 208,489 shares.
• Analysts have revised their price targets on Pulmonx shares, with Piper Sandler lowering it from $9.00 to $2.50 and Wells Fargo reducing it from $6.00 to $3.00, resulting in an average target price of $7.66.
• Pulmonx reported quarterly earnings with revenues of $23.86 million, exceeding expectations, but continues to show significant negative return on equity and net margins.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) CFO Mehul Joshi sold 7,936 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $1.60, for a total value of $12,697.60. Following the transaction, the chief financial officer directly owned 208,489 shares in the company, valued at approximately $333,582.40. This represents a 3.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Pulmonx Price Performance

Shares of LUNG remained flat at $1.74 during mid-day trading on Friday. The stock had a trading volume of 304,193 shares, compared to its average volume of 653,362. The stock has a market capitalization of $70.91 million, a PE ratio of -1.22 and a beta of 0.43. The firm's 50 day moving average is $2.25 and its 200-day moving average is $4.10. Pulmonx Corporation has a 1 year low of $1.47 and a 1 year high of $9.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.63 and a current ratio of 5.35.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%.The firm had revenue of $23.86 million during the quarter, compared to analyst estimates of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. Research analysts predict that Pulmonx Corporation will post -1.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Stifel Nicolaus dropped their price objective on Pulmonx from $16.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Piper Sandler cut Pulmonx from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $9.00 to $2.50 in a research note on Thursday, July 31st. Lake Street Capital dropped their price objective on Pulmonx from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Wall Street Zen raised Pulmonx from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Finally, D. Boral Capital dropped their price objective on Pulmonx from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Pulmonx has a consensus rating of "Moderate Buy" and an average target price of $7.66.

Institutional Trading of Pulmonx

Several hedge funds and other institutional investors have recently bought and sold shares of LUNG. Wells Fargo & Company MN boosted its position in Pulmonx by 48.7% during the 4th quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock valued at $125,000 after acquiring an additional 6,033 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Pulmonx by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 408,022 shares of the company's stock valued at $2,770,000 after acquiring an additional 60,489 shares in the last quarter. Stifel Financial Corp bought a new stake in Pulmonx during the 4th quarter valued at $81,000. Tudor Investment Corp ET AL boosted its position in Pulmonx by 9.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 149,102 shares of the company's stock valued at $1,012,000 after acquiring an additional 12,282 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Pulmonx by 2.9% during the 4th quarter. Northern Trust Corp now owns 372,659 shares of the company's stock valued at $2,530,000 after acquiring an additional 10,433 shares in the last quarter. Institutional investors own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.